Pitavastatin

Over long-term treatment (up to 2 years) in adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin maintained lipid-lowering efficacy with a generally favorable safety profile, and incidences of clinically significant myopathy or liver enzyme elevation were low.

A pooled analysis of randomized trials in adults with primary hyperlipidemia found that pitavastatin produced consistent, clinically meaningful reductions in LDL cholesterol and triglycerides with a safety and tolerability profile comparable to other statins at equivalent lipid-lowering doses.

Among adults with primary hypercholesterolemia, pitavastatin significantly reduced LDL cholesterol and non-HDL cholesterol compared with placebo, with a safety profile characterized mainly by mild adverse events and low discontinuation rates.

In adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin 1–4 mg once daily produced dose-dependent reductions in LDL cholesterol of roughly 31–44% versus placebo, with acceptable tolerability and low rates of treatment-limiting adverse events.

Across multiple clinical trials including adults with hypercholesterolemia but without diabetes at baseline, pitavastatin showed neutral or only minimal effects on fasting glucose and HbA1c and did not materially increase the incidence of new-onset diabetes compared with control therapy.

In adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin 1–4 mg once daily produced dose-dependent reductions in LDL cholesterol of roughly 31–44% versus placebo, with acceptable tolerability and low rates of treatment-limiting adverse events.

Among adults with primary hypercholesterolemia, pitavastatin significantly reduced LDL cholesterol and non-HDL cholesterol compared with placebo, with a safety profile characterized mainly by mild adverse events and low discontinuation rates.

Among adults with primary hypercholesterolemia, pitavastatin significantly reduced LDL cholesterol and non-HDL cholesterol compared with placebo, with a safety profile characterized mainly by mild adverse events and low discontinuation rates.

A pooled analysis of randomized trials in adults with primary hyperlipidemia found that pitavastatin produced consistent, clinically meaningful reductions in LDL cholesterol and triglycerides with a safety and tolerability profile comparable to other statins at equivalent lipid-lowering doses.

In adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin 1–4 mg once daily produced dose-dependent reductions in LDL cholesterol of roughly 31–44% versus placebo, with acceptable tolerability and low rates of treatment-limiting adverse events.

In middle-aged adults with HIV infection receiving pitavastatin or placebo for primary cardiovascular prevention over approximately 5 years, pitavastatin did not impair physical function tests, and clinically significant muscle symptoms occurred in about 5% of both groups, supporting good long-term tolerability.

In middle-aged adults with HIV infection receiving pitavastatin or placebo for primary cardiovascular prevention over approximately 5 years, pitavastatin did not impair physical function tests, and clinically significant muscle symptoms occurred in about 5% of both groups, supporting good long-term tolerability.

Over long-term treatment (up to 2 years) in adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin maintained lipid-lowering efficacy with a generally favorable safety profile, and incidences of clinically significant myopathy or liver enzyme elevation were low.

In adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin 1–4 mg once daily produced dose-dependent reductions in LDL cholesterol of roughly 31–44% versus placebo, with acceptable tolerability and low rates of treatment-limiting adverse events.

Over long-term treatment (up to 2 years) in adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin maintained lipid-lowering efficacy with a generally favorable safety profile, and incidences of clinically significant myopathy or liver enzyme elevation were low.

Across multiple clinical trials including adults with hypercholesterolemia but without diabetes at baseline, pitavastatin showed neutral or only minimal effects on fasting glucose and HbA1c and did not materially increase the incidence of new-onset diabetes compared with control therapy.

Among adults with primary hypercholesterolemia, pitavastatin significantly reduced LDL cholesterol and non-HDL cholesterol compared with placebo, with a safety profile characterized mainly by mild adverse events and low discontinuation rates.

In adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin 1–4 mg once daily produced dose-dependent reductions in LDL cholesterol of roughly 31–44% versus placebo, with acceptable tolerability and low rates of treatment-limiting adverse events.

Over long-term treatment (up to 2 years) in adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin maintained lipid-lowering efficacy with a generally favorable safety profile, and incidences of clinically significant myopathy or liver enzyme elevation were low.

In adults with primary hypercholesterolemia or combined dyslipidemia, pitavastatin 1–4 mg once daily produced dose-dependent reductions in LDL cholesterol of roughly 31–44% versus placebo, with acceptable tolerability and low rates of treatment-limiting adverse events.